Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||KDR positive|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KDR positive||Advanced Solid Tumor||predicted - sensitive||Anti-VEGFR2 CAR CD8 lymphocytes||Preclinical||Actionable||In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes, displayed efficacy in inhibiting cell and tumor growth in a variety of solid tumor cell lines and mouse tumor models (PMID: 20978347).||20978347|
|KDR positive||melanoma||predicted - sensitive||Anti-VEGFR2 CAR CD8 lymphocytes||Preclinical||Actionable||In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes increased survival of melanoma mouse models (PMID: 23633494).||23633494|
|KDR positive||pancreatic cancer||sensitive||TAS-115||Preclinical||Actionable||In a preclinical study, pancreatic islet endothelial cells were sensitive to TAS-115, resulting in decreased phosphorylation of Vegfr2, and inhibition of cell growth and angiogenesis in culture and mouse models (PMID: 24140932).||24140932|
|KDR positive||Advanced Solid Tumor||predicted - sensitive||Tanibirumab||Phase I||Actionable||In a Phase I trial, Tanibirumab treatment demonstrated manageable toxicity and preliminary efficacy, resulted in increased circulating Kdr (Vegfr2), Vegf and Pigf, and stable disease in 61% (11/18) of patients with refractory solid tumors (PMID: 28391576; NCT01660360).||28391576|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|